Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study

Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study

Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited representation of subjects with abnormal body weight, which were mostly limited to a BMI > 40 kg/m<sup>2</sup>, or body weight > 120 kg for obese subjects, and <50 kg for underweight...

Full description

Bibliographic Details
Main Authors: Łukasz Wołowiec, Mateusz Kusiak, Jacek Budzyński, Anna Wołowiec, Albert Jaśniak, Michał Wiciński, Agnieszka Pedrycz-Wieczorska, Daniel Rogowicz, Grzegorz Grześk
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Journal of Clinical Medicine
Subjects:
direct oral anticoagulants (DOACs)
atrial fibrillation
obesity
body weight
therapeutic drug monitoring
Online Access:https://www.mdpi.com/2077-0383/12/15/4969

Internet

https://www.mdpi.com/2077-0383/12/15/4969

Similar Items